GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Percheron Therapeutics PER.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.00

+33.33%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

—

FY2017FY2026

Net income

−A$4.8m

FY2017FY2026

Free cash flow

−A$5.0m

FY2017FY2026

Shareholders' equity

A$7.5m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue———A$384,920A$34,180A$4,180A$30,530A$66,170A$25,550A$69,115
Gross profit−A$219,565−A$67,978−A$79,425−A$95,199−A$89,218−A$103,319−A$107,601−A$5,377−A$6,413A$69,115
Research and developmentA$2.1mA$10.8mA$10.7mA$10.2mA$4.5mA$4.9mA$1.9mA$1.1mA$975,403A$1.1m
Operating income−A$5.6m−A$16.7m−A$14.9m−A$13.3m−A$7.6m−A$8.7m−A$6.7m−A$3.6m−A$2.6m−A$3.2m
Net income−A$4.8m−A$14.9m−A$11.9m−A$11.4m−A$5.8m−A$8.1m−A$5.9m−A$2.9m−A$2.3m−A$2.8m
Diluted earnings per share-0.00-0.01-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.02

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsA$8.2mA$12.4mA$14.5mA$12.8mA$22.4mA$7.0mA$5.4mA$3.7mA$4.8mA$2.5m
Cash and short-term investmentsA$4.1mA$10.2mA$11.9mA$11.0mA$19.2mA$6.0mA$4.1mA$2.9mA$4.3mA$1.9m
Total liabilitiesA$692,182A$2.4mA$5.2mA$2.9mA$1.3mA$1.3mA$821,229A$888,839A$580,860A$685,652
DebtA$27,786A$25,865A$39,874A$142,099A$227,403A$306,845A$135,265A$135,265A$2.4m—
Shareholders' equityA$7.5mA$10.0mA$9.4mA$10.0mA$21.1mA$5.7mA$4.5mA$2.8mA$4.2mA$1.9m
Shares outstanding1,372m1,087m932m724m687m612m522m435m382m165m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−A$5.0m−A$15.6m−A$10.1m−A$8.2m−A$7.8m−A$5.8m−A$3.9m−A$2.9m−A$2.3m−A$2.9m
Capital spending−A$7,935−A$7,240−A$3,606−A$29,291−A$3,913−A$8,349−A$10,262−A$4−A$3−A$15,575
Free cash flow−A$5.0m−A$15.7m−A$10.1m−A$8.2m−A$7.8m−A$5.8m−A$4.0m−A$2.9m−A$2.3m−A$2.9m
Dividends paid————−A$79,442−A$82,385−A$97,894———

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023
Revenue——————A$543,234A$543,234
Gross profit−A$200,446−A$19,119−A$31,854−A$36,124−A$32,020−A$47,405−A$47,708A$536,325
Operating income−A$2.4m−A$3.2m−A$8.1m−A$8.6m−A$8.9m−A$5.9m−A$7.6m−A$3.2m
Net income−A$1.7m−A$3.1m−A$6.4m−A$8.5m−A$7.2m−A$4.7m−A$6.1m−A$3.1m
Diluted earnings per share-0.00-0.00-0.01-0.01-0.01-0.01-0.01-0.00
Cash from operations−A$2.0m−A$2.0m−A$7.0m−A$8.0m−A$5.0m−A$4.0m−A$5.0m−A$2.0m
Total assetsA$8.2mA$7.9mA$12.4mA$17.9mA$14.5mA$20.0mA$12.8mA$12.8m
Cash and short-term investmentsA$4.1mA$4.5mA$10.2mA$17.4mA$11.9mA$17.2mA$11.0mA$11.0m
DebtA$27,786A$10,682A$25,865A$72,345A$39,874A$16,136A$236,176—
Shareholders' equityA$7.5mA$7.1mA$10.0mA$15.3mA$9.4mA$16.4mA$10.0mA$10.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-25.0%-8.3%6.2%
Net income-25.0%-9.9%6.7%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-0.9-0.7-0.6-3.8-11.5-14.8-11.5-13.3-4.3-1.4
Price to sales———111.0————388.356.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 6 Nov 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.